Whilst on it own the references to "advanced discussions is positive - and I firmly believe the outcome will be beneficial to holders. pushing the time frame from Q4 18 to Q2 19 (i.e. potentially missing by 6 months) does show some immaturity in understanding the complexities of this and future deals.
IMO, the company could do with some additional expertise in the pre-planning and execution of future deals. The market may accept this missed time frame (pending the quality of the deal) - but I wouldn't imagine there will be too many more such instances accepted. Lesson being - if you are not sure - don;t nominate a time frame - stick to "near future".
"Working closely with AGC and the Company’s Japanese advisors, it is anticipated that a licence agreement will be secured in Q2 FY19. The licensee will be responsible for the sponsorship and funding of the Company’s Phase 2 trial of Progenza for osteoarthritis and its commercialisation in Japan and will mark a significant next milestone in the Company’s progress towards commercialisation."
- Forums
- ASX - By Stock
- CMB
- Ann: FY18 Results and Business Update
Ann: FY18 Results and Business Update, page-4
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CMB (ASX) to my watchlist
(20min delay)
|
|||||
Last
35.0¢ |
Change
-0.045(11.4%) |
Mkt cap ! $4.175M |
Open | High | Low | Value | Volume |
39.0¢ | 39.0¢ | 35.0¢ | $46 | 127 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 75 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 1910 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 75 | 0.355 |
1 | 1917 | 0.350 |
1 | 2500 | 0.200 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 1910 | 1 |
0.500 | 51 | 1 |
0.545 | 13403 | 1 |
0.600 | 2000 | 1 |
0.670 | 7238 | 1 |
Last trade - 13.58pm 09/08/2024 (20 minute delay) ? |
Featured News
CMB (ASX) Chart |